Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Are investors too bearish on Australian equities?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,218.80 | 79.60 | -0.86% |
| CAC 40 | 8,200.88 | 15.70 | -0.19% |
| DAX 40 | 24,124.21 | 154.42 | -0.64% |
| Dow JONES (US) | 47,823.59 | 117.22 | 0.25% |
| FTSE 100 | 9,756.14 | 59.40 | 0.61% |
| HKSE | 26,346.14 | 87.56 | -0.33% |
| NASDAQ | 23,967.77 | 140.28 | 0.59% |
| Nikkei 225 | 51,307.65 | 1,088.47 | 2.17% |
| NZX 50 Index | 13,409.21 | 6.55 | 0.05% |
| S&P 500 | 6,903.84 | 12.95 | 0.19% |
| S&P/ASX 200 | 8,926.20 | 85.90 | -0.95% |
| SSE Composite Index | 3,988.22 | 8.72 | -0.22% |